Abstract:The phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) have been regarded as promising targets for the treatment of cancer. Herein, we synthesized a new series of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as novel PI3Ka/mTOR dual inhibitors for cancer therapy. All compounds were evaluated for the IC50 values against three cancer cell lines (A549, MCF-7 and Hela). Most of the target compounds exhibited moderate to excellent anti-tumor activities against these three tested cancer cell lines especially against A549 and Hela cancer cell lines. Among them, the most promising compound 13g showed excellent anti-tumor potency for A549, MCF-7 and Hela cell lines with IC50 values of 0.20 +/- 0.05 mu M, 1.25 +/- 0.11 mu M and 1.03 +/- 0.24 mu M, respectively. Notably, according to the result of enzymatic activity assay, compound 13g was identified as a novel PI3Ka/mTOR dual inhibitor, which had an approximately 10-fold improvement in mTOR inhibition, compared to the class I PI3K inhibitor 1 (pictilisib, GDC-0941), with IC50 values of 525 nM to 48 nM. And western blot analysis indicated compound 13g could efficiently suppress the phosphorylation of AKT at the dose of 0.1 mu M, which further demonstrated compound 13g had significant inhibitory effect on the PI3K/Akt/mTOR pathway. Furthermore, compound 13g could stimulate A549 cells arrest at G0/G1 phase in a dose-dependent manner, and induced apoptosis at a low concentration.

Design, Synthesis and in Vitro Biological Evaluation of 2-Aminopyridine Derivatives As Novel PI3Kδ Inhibitors for Hematological Cancer.

Design, Synthesis and Biological Evaluation of Novel Selective PI3Kδ Inhibitors Containing Pyridopyrimidine Scaffold.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Novel 3-Substituted Imidazo[1,2-A]pyridine and Quinazolin-4(3H)-one Derivatives As PI3Kα Inhibitors.

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one Derivatives As a PI3Kα Inhibitor.

Design, synthesis, and biological evaluation of novel bivalent PI3K inhibitors for the potential treatment of cancer

Design, Synthesis, and Biological Evaluation of Thieno[3,2‐d]pyrimidine Derivatives As Potential Simplified Phosphatidylinositol 3‐kinase Alpha Inhibitors

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Discovery of Novel Pyrido[3,2-D]pyrimidine Derivatives As Selective and Potent PI3Kδ Inhibitors.

Discovery of Pyrazolo[1,5- a ]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.

Design, Synthesis and Biological Evaluation of Substituted 2-(Thiophen-2-yl)-1,3,5-triazine Derivatives As Potential Dual PI3Kα/mTOR Inhibitors.

Design And Synthesis Of A Novel Series Of N,4-Diphenylpyrimidin-2-Amine Derivatives As Potent And Selective Pi3k Gamma Inhibitors

Design, synthesis and bioevaluation of PI3K-selective inhibitors as potential colorectal cancer drugs

Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia